Novel immunoinflammatory blood markers in Graves’ orbitopathy: insights into activity and severity Authors: Mahdi Abounoori, Mohsen Pourazizi, Mohsen Bahmani Kashkouli, Ozra Akha, Reza Jafari, Marzieh Movahedirad Published: 2024 ABSTRACT AbstractObjectiveThis prospective case–control study examined the novel immunoinflammatory markers obtained from blood counts of patients with Graves’ orbitopathy (GO), Graves’ disease (GD) and healthy subjects.MethodsDemographic data, white cell count parameters, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), platelet-to-neutrophil ratio (PNR), red cell distribution width (RDW), RDW-to-platelet ratio (RDW/PLT), MPV-to-lymphocyte ratio (MPV/ALC), eosinophil-to-lymphocyte ratio (ELR) and systemic immune-inflammatory index (SII) were evaluated. The European Group on Graves Orbitopathy scale and Clinical Activity Score were used for clinical activity and severity assessment.ResultsThe GO group showed significantly higher mean MPV (p˂0.001) and MPV/ALC (p=0.03) than the GD group. The PLR (p=0.02), MPV/ALC (p=0.04) and SII (p=0.04) were significantly higher in the GO than healthy group. A significantly higher absolute neutrophil count (p=0.005), NLR (p=0.001), MPV (p=0.001), MPV/ALC (p=0.003), MPV/PLT (p=0.04), RDW (p˂0.001), RDW/PLT (p=0.02) and SII (p=0.01) as well as lower ALC (p=0.01) and PNR (p˂0.001) was observed in the active than inactive GO. Moderate to severe GO group had a significantly higher NLR (p=0.006), PLR (p=0.04), ELR (p=0.006), MPV (p=0.03), MPV/ALC (p=0.002), RDW (p˂0.001), RDW/PLT (p=0.02) and SII (p=0.03) as well as a lower ALC (p=0.01) and PNR (p=0.01) than mild GO.ConclusionsThe MPV/ALC ratio and MPV levels may identify GD patients at risk of GO. The MPV, MPV/ALC, ALC, NLR, PLR, PNR, RDW, RDW/PLT, MPV/PLT and SII may help distinguish the GO activity and severity. However, the study’s small sample size and single-centre design may limit the generalisability of the results. Furthermore, the lack of longitudinal follow-up precludes assessing marker evolution over time. WHAT IS ALREADY KNOWN ON THIS TOPIC Cytokines and immunological processes are thought to play a role in the pathophysiology of Graves orbitopathy (GO). Abnormalities in complete blood cell count parameters, such as white blood cell characteristics and platelet indices, can provide valuable insights into the inflammatory and immune dysregulation underlying GO pathogenesis. Cytokines and immunological processes are thought to play a role in the pathophysiology of Graves orbitopathy (GO). Abnormalities in complete blood cell count parameters, such as white blood cell characteristics and platelet indices, can provide valuable insights into the inflammatory and immune dysregulation underlying GO pathogenesis. WHAT THIS STUDY ADDS The mean platelet volume-to-lymphocyte ratio (MPV/ALC) ratio and MPV levels may identify Graves’ disease patients at risk of GO. The MPV, MPV/ALC, ALC, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, platelet-to-neutrophil ratio, red cell distribution width (RDW), RDW-to-platelet ratio (RDW/PLT), MPV/PLT and systemic immune-inflammatory index may help distinguish the GO activity and severity. The mean platelet volume-to-lymphocyte ratio (MPV/ALC) ratio and MPV levels may identify Graves’ disease patients at risk of GO. The MPV, MPV/ALC, ALC, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, platelet-to-neutrophil ratio, red cell distribution width (RDW), RDW-to-platelet ratio (RDW/PLT), MPV/PLT and systemic immune-inflammatory index may help distinguish the GO activity and severity. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY This study’s findings on novel immunoinflammatory markers from blood counts in GO could revolutionise clinical practice by providing clinicians with valuable tools for early detection and personalised treatment strategies, potentially improving patient outcomes. Integration of these markers into diagnostic and management protocols may also influence healthcare policies, optimising resource allocation and enhancing the standard of care for individuals with GO. This study’s findings on novel immunoinflammatory markers from blood counts in GO could revolutionise clinical practice by providing clinicians with valuable tools for early detection and personalised treatment strategies, potentially improving patient outcomes. Integration of these markers into diagnostic and management protocols may also influence healthcare policies, optimising resource allocation and enhancing the standard of care for individuals with GO. Introduction Graves’ orbitopathy (GO) is the principal extrathyroidal symptom of Graves’ disease (GD).1 GO is an autoimmune inflammatory disorder that affects the soft tissue of the orbit; extraocular muscle involvement, proptosis, conjunctival inflammation and oedema may lead to visual difficulties.24 GO, described as an autoimmune inflammatory disease involving the orbit, affects approximately 2 subjects per 10 000 a year and 25%–50% of GD patients.1 The pathogenic autoimmune reaction is shown to be directed against cross-reactive autoantigens in the thyroid and retrobulbar tissues. Cytokines and immunological processes are thought to play a role in the pathophysiology of GO. The condition is characterised by tissue invasion by cytokine-producing inflammatory cells and significant remodelling of the ocular soft tissues.1 GO has two stages: the first is a progressive, active stage characterised by active inflammation and orbital tissue modelling, followed by an inactive phase in which clinical findings are stabilised. Most clinical symptoms and indicators of GO, such as upper eyelid retraction, conjunctival congestion, proptosis, restrictive strabismus and diplopia, are observed during the active phase.5 6 Because GO has a complicated pathophysiology and can compromise visual function and cosmetic appearance, earlier identification improves the promptness and appropriateness of referrals to specialised centres.7 8 Complete blood count (CBC)-derived parameters have piqued the interest of researchers during the last decade as cost-effective, conveniently accessible and widely used indices. White cell count parameters, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume-to-platelet ratio (MPV/PLT) and systemic immune-inflammatory index (SII) have already been studied in GO.911 However, there is no study evaluating the newer inflammatory markers in GO, including platelet-to-neutrophil ratio (PNR), red cell distribution width (RDW), RDW/PLT, RDW-to-haemoglobin (Hb) ratio (RDW/Hb), MPV-to-lymphocyte ratio (MPV/ALC), eosinophil-to-lymphocyte ratio (ELR), lymphocyte-to-monocyte ratio (LMR), the systemic inflammation response index (SIRI) and the pan immune inflammation value (PIV) which recently were evaluated in several inflammatory conditions like epidermal necrolysis, coronary heart disease, ovarian cancer and hypoxic-ischaemic encephalopathy.1215 Therefore, the present study aimed to investigate if the change in such inflammatory markers could be used to help diagnose the GO. Methods This case–control, prospective, single-centre study was conducted in a Mazandaran University of Medical Sciences hospital-affiliated ophthalmology and endocrinology outpatient clinics from September 2022 to September 2023. GD patients with and without GO were included. GD was diagnosed based on the presence of conventional symptoms of hyperthyroidism and confirmed by laboratory results, including positive serum TRAb (positive titre >1.75 IU/L), elevated levels of free triiodothyronine (fT3), free thyroxine (fT4) and decreased levels of thyroid-stimulating hormone (TSH).16 The European Group on Graves Orbitopathy (EUGOGO) agreement served as the basis for diagnosing GO.17 The healthy control group (H) comprised randomly selected healthy individuals over 18 years old, free from any chronic or acute illnesses with normal thyroid function, not on any regular medication that could affect the study outcomes, except for common over-the-counter medications like vitamins, not engaging in behaviours that could confound the study results, such as smoking or excessive alcohol consumption. Exclusion criteria for the study and control groups were age under 18 years, acute or chronic infection in the past 6 months, other autoimmune/inflammatory systemic or ocular diseases, ocular surgery or trauma history in the previous 12 months, traumatic eye injury at any time in the past, use of ocular or systemic medications with proven effect on blood counts, patients with antithyroid drug-induced neutropenia with neutrophil count <1.5×109/L were excluded, glucocorticoid usage in the previous 3 months, pregnancy, a history of malignancy or haematological diseases, thyroidectomy, radioiodine therapy prior to or after the diagnosis of GD and toxic nodular goitre.18 A priori power analysis was conducted by using G*Power V.3.1. Based on previous studies examining NLR in GD,19 we anticipated a medium effect size (Cohen’s d=0.6) for the difference in NLR between GO and GD groups. To achieve 80% power with a two-tailed alpha of 0.05, a minimum of 25 participants per group was required. Accounting for potential dropouts (10%), we aimed to recruit 30 participants per group. The Clinical Activity Score (CAS) included pain at rest and on eye motion, eyelid redness and swelling, conjunctival chemosis and diffuse redness, and inflammation of the caruncle and/or plica. Each parameter was assigned one point, and active GO was defined as CAS≥3/7.20 The EUGOGO scale was used for severity grading.21 Sociodemographic data, such as age, sex, family history of thyroid disease, duration of GD and GO, and smoking status, were collected. A current smoker was one who had smoked in the previous 28 days with more than 100 cigarettes in the lifetime (hand-rolled cigarettes, cigars and cigarillos).22 Blood sample was used for haematology tests as well as TSH (normal range: 0.55–4.78 mU/L), fT3 (normal range: 2.3–4.2 ng/L) and fT4 (normal range: 0.89–1.76 ng/dL) (Roche Cobas 8000 analyzer, Roche Diagnostic). The CBC ratios were as follows: NLR: absolute neutrophil/absolute lymphocyte. LMR: absolute lymphocyte/absolute monocyte. PLR: platelet/absolute lymphocyte. MLR: absolute monocyte/absolute lymphocyte. ELR: absolute eosinophil/absolute lymphocyte. PNR: platelet/absolute neutrophil. MPV/ALC: MPV/absolute lymphocyte. SIRI=neutrophil×monocyte/lymphocyte. SII=neutrophils×platelets/lymphocytes. PIV=neutrophil×platelets×monocytes/lymphocytes. The primary outcome measure was the change of CBC parameters for diagnosing the GO from the control and GD groups. Secondary outcomes were the change in CBC parameters between control vs GD, active versus inactive GO and mild versus moderate to severe GO. Statistical analysis SPSS statistics software (SPSS V.27.0 for Windows, IBM) was used for statistical analyses. Categorical variables were reported using frequency distribution tables (number and percentage), while quantitative variables were reported using mean SD and median with range. To assess the normality of the study variables, the Shapiro-Wilk test was used. When measurements did not have a normal distribution, the Mann-Whitney U or Kruskal-Wallis test was used to compare independent groups; when they did, the t-test or analysis of variance was used. Tukey’s test was used for post hoc analysis. The χ2 test was used to compare categorical variables, which were then reported as numbers and percentages. An analysis of covariance (ANCOVA) was used within the framework of a general linear model across independent groups to evaluate the differences in CBC parameters and ratios. Separate ANCOVAs were conducted for each inflammatory ratio and CBC parameter, treating them as the dependent variables. The diagnostic groups were set as fixed factors, while age, sex, smoking and family history of thyroid disease were included as covariates. A post hoc analysis with Bonferroni correction was then performed to examine the differences between the groups. Receiver operating characteristic (ROC) curves depicted the accuracy of CBC parameters in diagnosis patients with GO and GD from healthy controls, which were evaluated by calculating the area under the ROC curves (AUROC). A p<0.05 was considered statistically significant. A statistically significant p<0.05 was considered. Results Of 120 participants, 30 patients with proven GD, 30 with proven GO and 30 with healthy control were enrolled in the study (online supplemental figure 1). Age and gender were not significantly different between the three groups. Also, positive family history of thyroid disease, disease duration and smoking status (current smoker) were not significantly different between the GD with GO and GD without GO groups. The median duration of GO and GD in enrolled patients was 5 and 11 months (table 1). Table 1Comparing the characteristics between the study and control groupsGD with GO(n=30)GD without GO(n=30)Healthy control(n=30)P valueAge (year)44.47±15.9048.37±11.7243.47±16.990.40Sex, n (%) Female17 (56.7)23 (76.7)18 (60)0.22 Male13 (43.3)7 (23.3)12 (40)Current smoking, n (%)11 (36.7)5 (16.7)0 (0)0.14Positive family history of thyroid disease, n (%)20 (66.7)19 (63.3)0 (0)0.99.GD, Graves’ diseaseGO, Graves’ orbitopathy Comparing the characteristics between the study and control groups .GD, Graves’ diseaseGO, Graves’ orbitopathy In the GO group, 16 (53.3%) were active, 12 (40%) had mild and 18 (60%) had moderate to severe thyroid eye disease. Patients with moderate to severe GO were significantly older and current smokers and had a higher CAS (table 2). On the other hand, the frequency of active GO was significantly higher in the male gender, current smokers and more severe GO (table 2). Table 2Characteristics of 30 patients with GOActive GOInactive GOP valueMild GOModerate to severe GOP valueAge (year)48.81±17.0639.5±13.360.1136.25±12.5549.94±15.820.02Sex, n (%)0.030.14 Female6 (37.5)11 (78.6)9 (75)8 (44.4) Male10 (62.5)3 (21.4)3 (25)10 (55.6)Proptosis manifestation, n (%)0.080.01 None0 (0)3 (21.4)3 (25)0 (0) Bilateral9 (56.3)4 (28.6)2 (16.7)11 (61.1) Unilateral7 (43.8)7 (50)7 (58.3)7 (38.9) Lid traction, n (%)8 (50)4 (28.6)0.284 (33.3)8 (44.4)0.70 Smoking, n (%)9 (56.3)2 (14.3)0.021 (8.3)10 (55.6)0.01 Family history of thyroid disease, n (%)12 (75)8 (57.1)0.37 (58.3)13 (72.2)0.70EUGOGO0.002––– Mild2 (12.5)10 (71.4) Moderate to severe14 (87.5)4 (28.6) Sight-threatening0 (0)0 (0)CAS0.002 Active–––2 (16.7)14 (77.8) Inactive10 (83.3)4 (22.2)CAS, Clinical Activity ScoreEUGOGO, European Group on Graves Orbitopathy scale; GO, Graves’ orbitopathy Characteristics of 30 patients with GO CAS, Clinical Activity ScoreEUGOGO, European Group on Graves Orbitopathy scale; GO, Graves’ orbitopathy The mean values of absolute monocyte count (AMC), MPV, MPV/ALC and PLR were significantly different between the three groups (table 3), and all remained significant in the multivariate analysis (AMC, p=0.02; MPV, p˂0.001; MPV/ALC, p=0.02 and PLR, p=0.03). Table 3Selected CBC parameters in control, GD versus GOCBC parameters and ratiosGO (n=30)GD (n=30)H (n=30)P valueGO-GD-HP valueGO-GDP valueGO-HP valueGD-HWBC, ×109/L7.55±1.967.25±2.317.74±2.200.260.250.940.66ANC, ×109/L4.69±1.934.24±24.35±1.670.610.630.770.97ALC, ×109/L2.35±0.922.5±0.732.66±0.730.2370.750.30.97AMC, ×109/L0.34±0.240.28±0.240.47±0.280.020.670.10.01AEC, ×109/L0.17±0.10.22±0.230.24±0.250.260.580.40.95PLT, ×109/L245.72±64.04247.03±63.13235.8±61.350.7520.970.810.77TSH, mIU/L0.14±0.30.05±0.062.2±0.89 <0.001 0.08˂0.001˂0.001fT4, ng/dL21.03±21.3132.57±41.456.81±1.85 <0.001 0.480.10.001fT3, ng/dL7.45±16.7345.49±134.71.44±0.44 <0.001 0.380.950.08NLR2.4±1.671.8±0.891.67±0.660.3230.120.040.9LMR11.36±9.2614.96±12.879.56±10.180.090.420.810.16PLR114.7±38.88104.98±35.491.4±23.15 0.03 0.28 0.02 0.26MLR0.15±0.110.12±0.090.18±0.120.120.460.690.13ELR0.07±0.050.08±0.060.09±0.120.9350.960.720.87PNR60.88±28.166.3±25.9459.6±18.150.5360.670.980.54MPV, fL10.33±1.178.9±0.999.88±1.29 <0.001 <0.001 0.29 0.005 MPV/ALC5.12±2.263.92±1.463.98±1.140.0480.020.030.99MPV/PLT0.045±0.010.039±0.010.045±0.020.1270.150.990.16RDW, %13.49±1.2913.12±1.0713.53±1.310.3810.450.990.42Hb, g/dL13.43±1.9412.85±0.9913.9±1.6 0.03 0.260.48 0.03 RDW/Hb1.019±0.171.021±0.10.99±0.180.5360.990.860.83RDW/PLT0.059±0.0180.057±0.0170.062±0.020.6910.910.820.58SIRI0.79±0.720.53±0.740.82±0.610.0510.320.990.26SII579.4±386.66440.45±220.87398.97±174.620.3540.13 0.04 0.83PIV201.76±211.55126.76±143.97197.41±156.630.120.220.990.29AEC, absolute eosinophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; CBCcomplete blood countELR, eosinophil-to-lymphocyte ratio; fT3free triiodothyroninefT4free thyroxineGD, Graves’ disease; GO, Graves’ orbitopathy; H, healthy control; LMR, lymphocyte-to-monocyte ratio; MLR, monocyte-to-lymphocyte ratio; MPV/ALC, mean platelet volume-to-lymphocyte ratio; MPV/PLT, MPV-to-platelet ratio; NLR, neutrophil-to-lymphocyte ratio; PIV, pan immune inflammation value; PLR, platelet-to-lymphocyte ratio; PLT, platelet; PNR, platelet-to-neutrophil ratio; RDW, red cell distribution width; RDW/Hb, RDW-to-haemoglobin ratio; SII, systemic immune-inflammatory indexSIRI, systemic inflammation response index; TSHthyroid-stimulating hormoneWBC, white cell count Selected CBC parameters in control, GD versus GO AEC, absolute eosinophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; CBCcomplete blood countELR, eosinophil-to-lymphocyte ratio; fT3free triiodothyroninefT4free thyroxineGD, Graves’ disease; GO, Graves’ orbitopathy; H, healthy control; LMR, lymphocyte-to-monocyte ratio; MLR, monocyte-to-lymphocyte ratio; MPV/ALC, mean platelet volume-to-lymphocyte ratio; MPV/PLT, MPV-to-platelet ratio; NLR, neutrophil-to-lymphocyte ratio; PIV, pan immune inflammation value; PLR, platelet-to-lymphocyte ratio; PLT, platelet; PNR, platelet-to-neutrophil ratio; RDW, red cell distribution width; RDW/Hb, RDW-to-haemoglobin ratio; SII, systemic immune-inflammatory indexSIRI, systemic inflammation response index; TSHthyroid-stimulating hormoneWBC, white cell count The GO group showed significantly higher mean MPV and MPV/ALC values than the GD group in univariate analysis (table 3) and multivariate analysis (MPV, p˂0.001, 95% CI: 0.73 to 2.13 and MPV/ALC, p=0.03, 95% CI: 0.1 to 2.24). While univariate analysis showed a significantly higher NLR, PLR, MPV/ALC and SII in the GO than control group (table 3), PLR (p=0.02, 95% CI: 3.23 to 46.15), MPV/ALC (p=0.04, 95% CI: 0.05 to 2.25) and SII (p=0.04, 95% CI: 7.59 to 367.04) remained significant in the multivariate analysis. The AMC and MPV were significantly higher in the GD than the control group in both univariate (table 3) and multivariate analysis (p=0.02, 95% CI: −1.6 to −0.14 for MPV and p=0.01, 95% CI: −0.35 to –0.03 for AMC). Patients with active GO had a significantly higher absolute neutrophil count (ANC), NLR, MPV, MPV/ALC, MPV/PLT, RDW, RDW/PLT and SII and lower ALC and PNR than inactive patients in univariate analysis (table 4). All variables remained significant in multivariate analysis (p=0.005 for ANC, p=0.01 for ALC, p=0.001 for NLR, p˂0.001 for PNR, p=0.001 for MPV, p=0.003 for MPV/ALC, p=0.04 for MPV/PLT, p˂0.001 for RDW, p=0.02 for RDW/PLT and p=0.01 for SII). Table 4Selected CBC parameters in different activities and severity of GOCBC parameters and ratiosInactive GO (n=16)Active GO (n=14)P valueMild GO(n=18)Moderate to severe GO (n=12)P valueWBC, ×109/L7±2.018.03±1.770.167.36±2.197.68±1.640.68ANC, ×109/L3.68±1.55.57±1.86 0.005 3.88±1.725.23±1.920.06ALC, ×109/L2.79±1.041.96±0.61 0.02 2.97±1.041.93±0.560.001AMC, ×109/L0.37±0.270.31±0.20.790.37±0.280.32±0.311AEC, ×109/L0.16±0.080.17±0.120.950.14±0.070.18±0.120.25PLT, ×109/L261.41±66.74232±60.310.22259.56±60.76236.5±66.20.34TSH, mIU/L0.2±0.40.1±0.150.40.2±0.440.1±0.140.95fT4, ng/dL24.29±30.8618.18±5.880.6426.23±32.8817.56±6.60.6fT3, ng/dL6.48±8.78.3±21.760.126.59±9.398.02±20.480.3NLR1.41±0.643.26±1.820.0011.41±0.743.06±1.790.001LMR13.3±11.299.66±6.990.4215.02±12.558.92±5.360.17PLR102.01±36.42125.8±38.620.0996.86±40.37126.6±33.9 0.04 MLR0.14±0.110.17±0.110.350.12±0.090.17±0.110.22ELR0.06±0.030.09±0.050.110.05±0.020.09±0.05 0.006 PNR78.13±27.2545.79±19.03˂0.00176.25±30.250.64±21.67 0.009 MPV, fL9.65±1.0210.93±0.970.0019.77±1.1210.71±1.07 0.02 MPV/ALC3.88±1.446.22±2.320.0033.63±1.246.12±2.12 0.002 MPV/PLT0.039±0.0120.05±0.0150.040.04±0.010.05±0.02 0.07 RDW, %12.6±0.8514.27±1.1˂0.00112.48±1.0314.17±0.97 ˂0.001 Hb, g/dL12.75±1.2314±2.27 0.07 12.78±1.4213.87±2.150.14RDW/Hb0.99±0.141.04±0.20.50.99±0.171.04±0.180.42RDW/PLT0.051±0.0130.066±0.019 0.02 0.05±0.010.06±0.02 0.02 SIRI0.58±0.640.98±0.76 0.07 0.56±0.660.95±0.74 0.053 SII391.64±267.69743.7±406.5 0.008 395.57±395.57701.96±398.14 0.009 PIV174.15±234.18225.92±194.07 0.09 171.49±249.69221.94±186.88 0.07 AEC, absolute eosinophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; CBCcomplete blood countELR, eosinophil-to-lymphocyte ratio; fT3free triiodothyroninefT4free thyroxineGD, Graves’ disease; GO, Graves’ orbitopathy; H, healthy control; LMR, lymphocyte-to-monocyte ratio; MLR, monocyte-to-lymphocyte ratio; MPV/ALC, mean platelet volume-to-lymphocyte ratio; MPV/PLT, MPV-to-platelet ratio; NLR, neutrophil-to-lymphocyte ratio; PIV, pan immune inflammation value; PLR, platelet-to-lymphocyte ratio; PLT, platelet; PNR, platelet-to-neutrophil ratio; RDW, red cell distribution width; RDW/Hb, RDW-to-haemoglobin ratio; SII, systemic immune-inflammatory indexSIRI, systemic inflammation response index; TSHthyroid-stimulating hormoneWBC, white cell count Selected CBC parameters in different activities and severity of GO AEC, absolute eosinophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; CBCcomplete blood countELR, eosinophil-to-lymphocyte ratio; fT3free triiodothyroninefT4free thyroxineGD, Graves’ disease; GO, Graves’ orbitopathy; H, healthy control; LMR, lymphocyte-to-monocyte ratio; MLR, monocyte-to-lymphocyte ratio; MPV/ALC, mean platelet volume-to-lymphocyte ratio; MPV/PLT, MPV-to-platelet ratio; NLR, neutrophil-to-lymphocyte ratio; PIV, pan immune inflammation value; PLR, platelet-to-lymphocyte ratio; PLT, platelet; PNR, platelet-to-neutrophil ratio; RDW, red cell distribution width; RDW/Hb, RDW-to-haemoglobin ratio; SII, systemic immune-inflammatory indexSIRI, systemic inflammation response index; TSHthyroid-stimulating hormoneWBC, white cell count Moderate to severe GO patients had a significantly higher NLR, PLR, ELR, MPV, MPV/ALC, RDW, RDW/PLT, SII and lower ALC and PNR than mild GO in univariate analysis (table 4). All variables remained significant in multivariate analysis (p=0.01 for ALC, p=0.006 for NLR, p=0.04 for PLR, p=0.006 for ELR, p=0.01 for PNR, p=0.03 for MPV, p=0.002 for MPV/ALC, p=0.02 for MPV/PLT, p=0.02 for RDW/PLT, p˂0.001 for RDW and p=0.03 for SII). The ANCOVA results reveal significant differences in several key parameters among GO, GD and H groups. Thyroid function tests showed significant alterations: TSH (p=0.00 for GO-GD-H, GO-H and GD-H), fT4 (p=0.01 for GO-GD-H and GD-H) and fT3 (p=0.02 for GO-GD-H and GD-H), confirming thyroid hormone dysregulation in GD. Platelet-related parameters, including MPV (p=0.00 for GO-GD-H and GO-GD, p=0.01 for GD-H) and MPV/PLT ratio (p=0.01 for GO-GD-H and GD-H), demonstrated significant differences. Hb levels also differed significantly (p=0.02 for GO-GD-H, p=0.01 for GD-H). Furthermore, the ANC was significantly higher in the active GO group than in the inactive group (p=0.03). The NLR also showed significant increases in both active GO (p=0.002) and moderate to severe GO cases (p=0.02). Additionally, PLR was higher in moderate to severe GO compared with mild cases (p=0.04), while the PNR was significantly lower in the active GO group (p=0.01). Specifically, MPV/ALC was significantly higher in the active GO group compared with the inactive group (p=0.04) and in moderate to severe GO compared with mild cases (p=0.04). Moreover, RDW and the SII were elevated in more severe or active cases (RDW: p=0.004 and p=0.007; SII: p=0.01 and p=0.04, respectively) (online supplemental tables 1 and 2). An AUROC (p=0.01) showed that the PLR at a cut-off value of 107.3 with a sensitivity of 60% and specificity of 80% could be used to diagnose the GO from the healthy group (onlinesupplemental figure 2 table 3). To differentiate GO from GD, MPV (cut-off value of 9.95) and MPV/ALC (cut-off value of 5.59) showed a significant AUROC (p=0.00 and 0.02). Their sensitivity was 70% and 40%, and specificity was 90% (for both) (onlinesupplemental figure 3 table 3). Discussion This study’s main findings revealed that PLR at a cut-off value of 0.69 with a sensitivity of 60% and specificity of 80% could be used to diagnose the GO from the healthy group. In addition, to diagnosing GO from GD, MPV (cut-off value of 9.95) and MPV/ALC (cut-off value of 5.59) with sensitivity of 70% and 40% and specificity of 90% (for both) could be helpful. Similarly, previous studies on CBC-driven inflammatory markers in patients with GO showed significant differences in PLR and SII between GO and healthy groups.9 10 In one study with the same topic, the AUC for PLR was defined as 0.64, the same as our findings (0.69). Although they reported the same sensitivity (64.2%) as us, they reported lower specificity (50.1%), which could be due to the smaller sample size in our study.9 While we found significant differences regarding MPV and MPV/ALC between GO and GD groups, the same study on this topic reported non-significant differences regarding MPV between them.10 These elevated MPV values might result from ongoing, subclinical systemic inflammation, even if the patients experience the disease’s inactive phase.23 Also, MPV represents platelet size and activity; the highest volume is reported in GD patients with GO.24 A systematic review and meta-analysis of PLT abnormalities in autoimmune thyroid diseases further indicate that the cause of MPV abnormalities may be immunological and inflammatory rather than hormonal.25 Patients with active GO had a significantly higher ANC, NLR, MPV, MPV/ALC, MPV/PLT, RDW, RDW/PLT, and SII and lower ALC and PNR than inactive patients. Moderate to severe GO patients had higher NLR, PLR, ELR, MPV, MPV/ALC, MPV/PLT, RDW, RDW/PLT, SII, and lower ALC and PNR than mild GO. Also, the GD group had higher AMC and MPV than the healthy group. Similar studies found significant differences in mean MPV, NLR, PLR and SII between GO and healthy groups as well as in active and inactive types.9 10 23 26 Additionally, while a study on CBC ratios, clinical characteristics and smoking status in patients with GO reported lower MPV/PLT values in active patients, our data relating to higher MPV/PLT in active GO than in inactive GO were conflicting.10 A systematic review on PLT abnormalities in autoimmune thyroid diseases reported that patients with GD had higher MPV than healthy controls. Also, they demonstrated that PLT had no significant differences between GD and healthy groups.25 This study had similar results regarding significantly higher MPV and no significant differences in PLT between GD, GO and healthy groups. So, this meta-analysis justifies our results regarding higher MPV/PLT values in active and moderate to severe GO patients. Based on the results, we found that patients with active disease and moderate to severe severity had lower ALC than those with inactive and mild diseases. Similar to our findings, it has been postulated that ALC may provide information regarding GO disease activity or prognosis, in which lower ALC was associated with active and poor prognosis diseases.9 27 Lymphocytes are primarily responsible for mediating the inflammatory response, and a drop in lymphocyte count may result in higher inflammatory damage.28 Moreover, our results showed that patients with severe and active disease had lower PNR. Previously, the autoimmune origin of thrombocytopenia in GD and the overlap of thyroid and platelet autoimmunity were thoroughly elucidated.29 In addition, several studies demonstrated that autoimmune thyroid disease may develop autoantibodies against platelets.3032 Finally, increased neutrophils due to inflammation31 and lower platelet count may lead to decreased PNR. Furthermore, in this study, GO patients with active and severe disease had significantly higher RDW and RDW/PLT than inactive and mild forms. Several studies have recently shown that the amount of RDW is increased in many kinds of medical conditions and is highly linked with the degree of inflammation.3335 The study’s limitations included small sample size, the lack of information on additional well-established inflammatory markers like highly sensitive C reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), TNF-α, IL-1 and IL-6 with which to compare our findings, and subgroup analysis according to the smoking state. Additionally, the study was not intended to identify the pathways that result in changes in CBC parameters and ratios. Furthermore, the study strengths were the study’s prospective nature and study of novel inflammatory markers like MPV/ALC, PNR, ELR, MPV/PLT and RDW/PLT, which have not been studied in GO before. Because prompt thyroid dysfunction correction is linked to a lower risk of progression of initially mild or absent GO and the success of immunosuppressive treatment for more severe forms of GO is inversely correlated with disease duration, early diagnosis and management of GD and GO are essential.36 Mild ocular inflammatory signs were misdiagnosed as conjunctivitis or allergic reactions in one-fourth of patients in a statewide UK study, delaying the actual diagnosis of GO by up to a year.37 So, a CBC analysis could facilitate the GO diagnosis and management and prevent complications. This study has several important limitations that should be considered when interpreting the results. First, the cross-sectional design prevents assessment of how these blood markers change longitudinally within individual patients as GD potentially progresses to GO. This limits our ability to draw conclusions about the temporal relationship between changes in these markers and disease progression or activity. Second, the sample size was relatively small, with only 30 patients in each group, which may limit the statistical power and generalisability of the findings because of limitations in resources, like funding and availability of participants, necessitating a smaller sample size. Third, the study was conducted at a single centre, which could introduce selection bias and limit the diversity of the patient population. Fourth, while efforts were made to exclude confounding factors, there may be unmeasured variables influencing the blood markers that were not accounted for. Finally, the study did not include an assessment of other established inflammatory markers like CRP or ESR, which could have provided additional context for interpreting the novel markers examined. Future longitudinal studies with larger, multicentre cohorts and more comprehensive biomarker panels are needed to validate and expand on these findings. Conclusions Mean platelet levels and the MPV/ALC ratio may aid in identifying patients at the highest risk of developing GO during GD, which tended to be active and moderate to severe disease requiring more robust endocrine and radiological management. In addition to MPV and MPV/ALC, the ALC, NLR, PLR, PNR, MPV/PLT, RDW, RDW/PLT and SII could help differentiate between active and inactive as well as mild and moderate to severe phases of the disease. supplementary material